title: The influence of demographic factors and health-related quality of life on treatment satisfaction in patients with gastroesophageal reflux disease treated with esomeprazole.
abstract: BACKGROUND
  The correlation between treatment satisfaction and demographic characteristics, symptoms, or health-related quality of life (HRQL) in patients with gastroesophageal reflux disease (GERD) is unknown. The objective of this study was to assess correlates of treatment satisfaction in patients with GERD receiving a proton pump inhibitor, esomeprazole.
  
  
  METHODS
  Adult GERD patients (n = 217) completed demography, symptom, HRQL, and treatment satisfaction questionnaires at baseline and/or after treatment with esomeprazole 40 mg once daily for 4 weeks. We used multiple linear regressions with treatment satisfaction as the dependent variable and demographic characteristics, baseline symptoms, baseline HRQL, and change scores in HRQL as independent variables.
  
  
  RESULTS
  Among the demographic variables only Caucasian ethnicity was positively associated with treatment satisfaction. Greater vitality assessed by the Quality of Life in Reflux and Dyspepsia (QOLRAD) and worse heartburn assessed by a four-symptom scale at baseline, were associated with greater treatment satisfaction. The greater the improvement on the QOLRAD vitality (change score), the more likely the patient is to be satisfied with the treatment.
  
  
  CONCLUSIONS
  Ethnicity, baseline vitality, baseline heartburn severity, and change in QOLRAD vitality correlate with treatment satisfaction in patients with GERD.
authors.affiliation: AstraZeneca R&D, 431 83 Mölndal, Sweden. alessio.deglinnocenti@astrazeneca.com
authors.forename: Alessio
authors.initials: A
authors.lastname: Degl' Innocenti
authors.forename: Gordon H
authors.initials: GH
authors.lastname: Guyatt
authors.forename: Ingela
authors.initials: I
authors.lastname: Wiklund
authors.forename: Diane
authors.initials: D
authors.lastname: Heels-Ansdell
authors.forename: David
authors.initials: D
authors.lastname: Armstrong
authors.forename: Carlo A
authors.initials: CA
authors.lastname: Fallone
authors.forename: Lisa
authors.initials: L
authors.lastname: Tanser
authors.forename: Sander Veldhuyzen
authors.initials: SV
authors.lastname: van Zanten
authors.forename: Samer
authors.initials: S
authors.lastname: El-Dika
authors.forename: Naoki
authors.initials: N
authors.lastname: Chiba
authors.forename: Alan N
authors.initials: AN
authors.lastname: Barkun
authors.forename: Peggy
authors.initials: P
authors.lastname: Austin
authors.forename: Holger J
authors.initials: HJ
authors.lastname: Schünemann
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002170:Canada; D003710:Demography; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D064098:Esomeprazole / Q000627:therapeutic use*; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D006356:Heartburn / Q000503:physiopathology / Q000523:psychology; D006801:Humans; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction / Q000706:statistics & numerical data*; D011788:Quality of Life; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D004791:Enzyme Inhibitors; D064098:Esomeprazole